New treatment targets prostate cancer
Researchers at the Prostate and Breast Cancer Research Program at Monash University claim to have found a treatment using oestrogens to treat castrate-resistant cells in recurrent prostate cancer.
They used a drug that is developed to activate selectively and specifically the beta oestrogen receptor in the prostate, which not only inhibits cancer growth but also kills off cancer cells that are resistant to the conventional androgen deprivation therapy.
The researchers report discovering how this compound, working through the beta receptors, targets a small but important population of cells in the tumour.
They made their discovery in animal models and then replicated laboratory results using human cells and tissues from patients with prostate cancer.
Published: 04 Apr 2010